Thursday, August 22, 2024

🌎 Hims & Hers Health Initiated, SentinelOne Upgraded, Goosehead Insurance Downgraded and more...

Ratings changes for Sangamo Therapeutics, Crocs, Esperion Therapeutics, Milestone Pharmaceuticals, Urban Outfitters, Provident Financial, NVIDIA and more...Upgrade to MarketBeat All Access to get early delivery, personalized stock alerts, portfolio monitoring tools, and more. Start Your Free Trial.
August 22nd, 2024
S and P pricesDow pricesQQQ prices
Follow MarketBeat on Twitter Join the MarketBeat Facebook Group Subscribe on YouTube 


Your Watchlist (Manage Your Watchlist and Monitor Your Portfolio)

Analysts' Upgrades
  • Bilibili (NASDAQ:BILI) was upgraded by analysts at Nomura from a "neutral" rating to a "buy" rating. They now have a $18.00 price target on the stock. This represents a 26.6% upside from the current price of $14.22.
  • Crocs (NASDAQ:CROX) was upgraded by analysts at Williams Trading from a "hold" rating to a "buy" rating. They now have a $163.00 price target on the stock, up previously from $135.00. This represents a 13.5% upside from the current price of $143.62.
  • EstΓ©e Lauder Companies (NYSE:EL) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $114.00 price target on the stock, up previously from $95.00. This represents a 22.7% upside from the current price of $92.89.
  • Navigator (NYSE:NVGS) was upgraded by analysts at Clarkson Capital from a "neutral" rating to a "buy" rating. They now have a $20.00 price target on the stock. This represents a 22.2% upside from the current price of $16.36.
  • SentinelOne (NYSE:S) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $29.00 price target on the stock, up previously from $19.00. This represents a 15.5% upside from the current price of $25.11.
  • Unilever (NYSE:UL) was upgraded by analysts at Bank of America Co. from an "underperform" rating to a "buy" rating. They now have a $72.00 price target on the stock, up previously from $47.00. This represents a 14.9% upside from the current price of $62.66.
  • Select Water Solutions (NYSE:WTTR) was upgraded by analysts at Northland Securities from a "market perform" rating to an "outperform" rating. They now have a $14.50 price target on the stock. This represents a 30.3% upside from the current price of $11.13.
  • View today's most recent analysts' upgrades at MarketBeat.com right arrow


Analysts' Downgrades
  • Assurant (NYSE:AIZ) was downgraded by analysts at Piper Sandler from an "overweight" rating to a "neutral" rating. They now have a $200.00 price target on the stock. This represents a 6.5% upside from the current price of $187.87.
  • Goosehead Insurance (NASDAQ:GSHD) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to a "market perform" rating. They now have a $90.00 price target on the stock. This represents a 11.5% upside from the current price of $80.73.
  • ItaΓΊ Unibanco (NYSE:ITUB) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.The current price is $6.61.
  • Sprout Social (NASDAQ:SPT) was downgraded by analysts at KeyCorp from a "sector weight" rating to an "underweight" rating. They now have a $28.00 price target on the stock. This represents a 12.9% downside from the current price of $32.13.
  • TJX Companies (NYSE:TJX) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "neutral" rating. They now have a $128.00 price target on the stock, up previously from $110.00. This represents a 6.0% upside from the current price of $120.70.
  • Urban Outfitters (NASDAQ:URBN) was downgraded by analysts at Telsey Advisory Group from an "outperform" rating to a "market perform" rating. They now have a $44.00 price target on the stock, down previously from $49.00. This represents a 17.8% upside from the current price of $37.36.
  • View today's most recent analysts' downgrades at MarketBeat.com right arrow


Analysts' New Coverage
  • Altus Midstream (NASDAQ:ALTM) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "hold" rating and a $3.00 price target on the stock. This represents a 4.2% upside from the current price of $2.88.
  • BrightView (NYSE:BV) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $16.00 price target on the stock. This represents a 3.6% upside from the current price of $15.44.
  • CubeSmart (NYSE:CUBE) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $53.00 price target on the stock. This represents a 6.2% upside from the current price of $49.90.
  • Dada Nexus (NASDAQ:DADA) is now covered by analysts at Daiwa Capital Markets. They set a "neutral" rating on the stock.The current price is $1.30.
  • Journey Medical (NASDAQ:DERM) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $9.00 price target on the stock. This represents a 96.9% upside from the current price of $4.57.
  • Emergent BioSolutions (NYSE:EBS) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $16.00 price target on the stock. This represents a 60.6% upside from the current price of $9.96.
  • EPAM Systems (NYSE:EPAM) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "hold" rating and a $204.00 price target on the stock. This represents a 1.7% upside from the current price of $200.50.
  • FedEx (NYSE:FDX) is now covered by analysts at TD Cowen. They set a "buy" rating and a $334.00 price target on the stock. This represents a 14.7% upside from the current price of $291.21.
  • Flutter Entertainment (NYSE:FLUT) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $247.00 price target on the stock. This represents a 17.4% upside from the current price of $210.42.
  • Globant (NYSE:GLOB) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "hold" rating and a $210.00 price target on the stock. This represents a 2.7% upside from the current price of $204.49.
  • Hims & Hers Health (NYSE:HIMS) is now covered by analysts at Needham & Company LLC. They set a "buy" rating and a $24.00 price target on the stock. This represents a 42.9% upside from the current price of $16.80.
  • INmune Bio (NASDAQ:INMB) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $22.00 price target on the stock. This represents a 228.8% upside from the current price of $6.69.
  • Disc Medicine (NASDAQ:IRON) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $75.00 price target on the stock. This represents a 52.3% upside from the current price of $49.26.
  • Milestone Pharmaceuticals (NASDAQ:MIST) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $9.00 price target on the stock. This represents a 508.1% upside from the current price of $1.48.
  • Orchestra BioMed (NASDAQ:OBIO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $14.00 price target on the stock. This represents a 122.2% upside from the current price of $6.30.
  • Palantir Technologies (NYSE:PLTR) is now covered by analysts at Northland Securities. They set a "market perform" rating and a $35.00 price target on the stock. This represents a 7.6% upside from the current price of $32.53.
  • Tectonic Therapeutic (NASDAQ:TECX) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $55.00 price target on the stock. This represents a 230.1% upside from the current price of $16.66.
  • Tandem Diabetes Care (NASDAQ:TNDM) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $45.00 price target on the stock. This represents a 6.2% upside from the current price of $42.39.
  • Unity Biotechnology (NASDAQ:UBX) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $8.00 price target on the stock. This represents a 411.2% upside from the current price of $1.57.
  • United Parcel Service (NYSE:UPS) is now covered by analysts at TD Cowen. They set a "hold" rating on the stock.The current price is $126.88.
  • UroGen Pharma (NASDAQ:URGN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $40.00 price target on the stock. This represents a 162.1% upside from the current price of $15.26.
  • View today's most recent analysts' new coverage at MarketBeat.com right arrow

Upgrade Your Subscription
Manage Your Watchlist
Join Our Facebook Group

Thank you for subscribing to MarketBeat!
We empower individual investors to make better trading decisions by providing real-time financial information and objective market research. MarketBeat is a small business and email is a crucial tool for us to share information, news, trading ideas and financial products and services with our subscribers (that's you!). If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
 
If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.
 
© 2006-2024 MarketBeat Media, LLC.
345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.
 
Today's Bonus Content: It's over.

No comments:

Post a Comment

You ➕ this quiz 🟰 A certified genius

        Happy Friday! I think by now you've gathered that Fridays are for trivia, right? Of course you did because you're smart...